Global Biopsy Devices Market Industry: Market Size & Forecast 2026

Biopsy devices are essential diagnostic tools used across hospitals, diagnostic laboratories, and ambulatory surgical centers to obtain tissue specimens for pathological examination. The market encompasses needle-based biopsy instruments, vacuum-assisted devices, core needle systems, and biopsy forceps, among others. Valued at approximately $2.54 billion in 2025, the market has experienced steady growth as healthcare providers increasingly rely on tissue-based diagnostics for treatment planning and disease monitoring, particularly in oncology applications.

• •Market valued at approximately $2.54 billion in 2025 with consistent growth trajectory through the decade
• •Primary applications in cancer diagnosis, infectious disease identification, and transplant monitoring
• •Served by hospitals, diagnostic imaging centers, and specialized pathology laboratories

Rising global cancer incidence remains the primary market driver, as biopsies are the gold standard for confirming malignancies and guiding treatment decisions. Advancements in imaging-guided biopsy techniques have reduced procedure invasiveness while improving diagnostic accuracy, expanding adoption across healthcare settings. Growing awareness of early detection benefits and government screening initiatives in developing regions further stimulate market expansion.

• •Increasing prevalence of cancer and other chronic diseases worldwide
• •Technological innovations in imaging-guided and automated biopsy systems
• •Expanding elderly populations requiring more diagnostic interventions

The market is typically segmented by product type into needle-based biopsy instruments, biopsy guns, biopsy forceps, and vacuum-assisted devices, with needle-based systems representing the largest category due to their versatility and minimally invasive nature. By application, breast cancer biopsies and lung biopsies represent significant segments, though prostate, liver, and gastrointestinal applications also command substantial share. Geographically, North America leads market share due to advanced healthcare infrastructure and high cancer screening rates, while Asia-Pacific emerges as the fastest-growing region driven by improving healthcare access and rising disease burden.

• •Needle-based biopsy instruments dominate product segmentation across clinical settings
• •North America maintains largest regional share, with Asia-Pacific showing highest growth rates
• •Hospital end-users represent the primary distribution channel, with growing shift toward ambulatory settings

What are the recent trends and outlook?

Emerging trends include increasing adoption of MRI-compatible and ultrasound-guided biopsy systems, as well as artificial intelligence-assisted image guidance to improve targeting precision. Liquid biopsy technologies, while complementary rather than substitutive, are creating new diagnostic paradigms that may influence traditional tissue biopsy volumes. The market is expected to sustain moderate growth through the early 2030s as healthcare systems continue prioritizing precision medicine and personalized treatment approaches requiring tissue-based molecular testing.

• •Integration of AI and robotics into biopsy procedures for enhanced accuracy
• •Rising demand for liquid biopsy platforms creating complementary rather than replacement market dynamics
• •Focus on single-use disposable devices to reduce infection risk and procedural complications